CTC
RVNC

Central Trust Company’s Revance Therapeutics, Inc. RVNC Stock Holding History

Central Trust Company’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50
Closed -$260 – 1520
2024
Q3 		$260 Hold
50
– – ﹤0.01% 1387
2024
Q2 		$129 Hold
50
– – ﹤0.01% 1403
2024
Q1 		$246 Hold
50
– – ﹤0.01% 1359
2023
Q4 		$440 Hold
50
– – ﹤0.01% 1356
2023
Q3 		$574 Hold
50
– – ﹤0.01% 1336
2023
Q2 		$1.27K Hold
50
– – ﹤0.01% 1191
2023
Q1 		$1.61K Hold
50
– – ﹤0.01% 1200
2022
Q4 		$923 Hold
50
– – ﹤0.01% 1204
2022
Q3 		$1K Buy
+50
New +$1.01K ﹤0.01% 1285

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Central Trust Company's RVNC Position: Q4 2024 in Review

Central Trust Company sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 50 shares — an estimated $260 sold.

Central Trust Company first reported a position in RVNC in Q3 2022 and held it in 9 quarters. The position peaked at $1.61K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Central Trust Company reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Central Trust Company sold 50 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $260.
  • Central Trust Company first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 9 quarters.
  • Central Trust Company's Revance Therapeutics, Inc. position peaked at $1.61K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Central Trust Company's 13F filing for Q4 2024, filed 24 Jan 2025.